Literature DB >> 30307769

Farnesoid X receptor-α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo.

Karim Mouzannar1, Floriane Fusil1, Benoît Lacombe1, Anaïs Ollivier1, Camille Ménard1, Vincent Lotteau1, François-Loïc Cosset1, Christophe Ramière1,2, Patrice André1.   

Abstract

Hepatitis B virus (HBV) infection and bile acid (BA) metabolism are interdependent: infection modifies the expression of the BA nuclear receptor farnesoid X receptor (FXR)-α, and modulation of FXRα activity by ligands alters HBV replication. Mechanisms of HBV control by FXRα remain to be unveiled. FXRα silencing in HBV-infected HepaRG cells decreased the viral covalently closed circular (ccc)DNA pool size and transcriptional activity. Treatment with the FXRα agonist GW4064 inhibited FXRα proviral effect on cccDNA similarly for wild-type and hepatitis B viral X protein (HBx)-deficient virus, whereas agonist-induced inhibition of pregenomic and precore RNA transcription and viral DNA secretion was HBx dependent. These data indicated that FXRα acts as a proviral factor by 2 different mechanisms, which are abolished by FXRα stimulation. Finally, infection of C3H/HeN mice by a recombinant adeno-associated virus-2/8-HBV vector induced a sustained HBV replication in young mice in contrast with the transient decline in adult mice. Four-week GW4064 treatment of infected C3H/HeN mice decreased secretion of HBV DNA and HB surface antigen in adult mice only. These results suggest that the physiologic balance of FXRα expression and activation by bile acid is a key host metabolic pathway in the regulation of HBV infection and that FXRα can be envisioned as a target for HBV treatment.-Mouzannar, K., Fusil, F., Lacombe, B., Ollivier, A., Ménard, C., Lotteau, V., Cosset, F.-L., Ramière, C., André, P. Farnesoid X receptor α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo.

Entities:  

Keywords:  HBx; agonist; bile acids; mouse model; rAAV-HBV

Mesh:

Substances:

Year:  2018        PMID: 30307769     DOI: 10.1096/fj.201801181R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

Review 1.  Circadian Rhythms Coordinated With Gut Microbiota Partially Account for Individual Differences in Hepatitis B-Related Cirrhosis.

Authors:  Tongyao Wang; Xingyu Rong; Chao Zhao
Journal:  Front Cell Infect Microbiol       Date:  2022-07-01       Impact factor: 6.073

Review 2.  Novel therapeutic strategies for chronic hepatitis B.

Authors:  Sandra Phillips; Ravi Jagatia; Shilpa Chokshi
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

3.  The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1.

Authors:  Yajun Li; Yongming Fu; Xingwang Hu; Lunquan Sun; Daolin Tang; Ning Li; Fang Peng; Xue-Gong Fan
Journal:  Cell Death Dis       Date:  2019-05-28       Impact factor: 8.469

4.  Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesis.

Authors:  Yanchao Pan; Zhiyi Ke; Hong Ye; Lina Sun; Xiaoyan Ding; Yun Shen; Runze Zhang; Jing Yuan
Journal:  Inflamm Res       Date:  2019-09-17       Impact factor: 4.575

5.  Fibroblast growth factor 11 inhibits foot-and-mouth disease virus gene expression and replication in vitro.

Authors:  Hyo Rin Kang; Mi So Seong; Hyung-Soon Yim; Jung-Hyun Lee; Sang Ho Cha; Jaehun Cheong
Journal:  J Vet Med Sci       Date:  2022-04-05       Impact factor: 1.105

6.  Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study.

Authors:  Robin Erken; Patrice Andre; Elise Roy; Neeltje Kootstra; Noelie Barzic; Hugo Girma; Christian Laveille; Pauline Radreau-Pierini; Raphael Darteil; Jacky Vonderscher; Pietro Scalfaro; Pisit Tangkijvanich; Robert Flisiak; Henk Reesink
Journal:  J Viral Hepat       Date:  2021-09-29       Impact factor: 3.517

Review 7.  Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection.

Authors:  Lung-Yi Mak; Wai-Kay Seto; Man-Fung Yuen
Journal:  Viruses       Date:  2021-06-18       Impact factor: 5.048

Review 8.  Medicinal chemistry strategies toward host targeting antiviral agents.

Authors:  Xingyue Ji; Zhuorong Li
Journal:  Med Res Rev       Date:  2020-02-14       Impact factor: 12.944

Review 9.  Host Transcription Factors in Hepatitis B Virus RNA Synthesis.

Authors:  Kristi L Turton; Vanessa Meier-Stephenson; Maulik D Badmalia; Carla S Coffin; Trushar R Patel
Journal:  Viruses       Date:  2020-01-30       Impact factor: 5.048

10.  Impact on Bile Acid Concentrations by Alveolar Echinococcosis and Treatment with Albendazole in Mice.

Authors:  Cristina Gómez; Fadi Jebbawi; Michael Weingartner; Junhua Wang; Simon Stücheli; Bruno Stieger; Bruno Gottstein; Guido Beldi; Britta Lundström-Stadelmann; Alex Odermatt
Journal:  Metabolites       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.